This Article Full Text Full Text (PDF) All Versions of this Article: 114/13/1410    most recent CIRCULATIONAHA.105.605527v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Modesti, P. A. Articles by Parati, G. Search for Related Content PubMed PubMed Citation Articles by Modesti, P. A. Articles by Parati, G. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB OXYGEN Medline Plus Health Information Pulmonary Hypertension Related Collections Cardio-renal physiology/pathophysiology Cardiovascular Pharmacology Primary prevention Pulmonary circulation and disease Other Treatment

(Circulation. 2006;114:1410-1416.)
© 2006 American Heart Association, Inc.

Vascular Medicine

Role of Endothelin-1 in Exposure to High Altitude

Acute Mountain Sickness and Endothelin-1 (ACME-1) Study

Pietro Amedeo Modesti, MD, PhD; Simone Vanni, MD, PhD; Marco Morabito, PhD; Alessandra Modesti, BS, PhD; Matilde Marchetta, BS; Tania Gamberi, BS, PhD; Francesco Sofi, MD, PhD; Giulio Savia, MD; Giuseppe Mancia, MD; Gian Franco Gensini, MD; Gianfranco Parati, MD, PhD

From Clinica Medica Generale e Cardiologia (P.A.M., S.V., M. Morabito, A.M., M. Marchetta, T.G., F.S., G.F.G.), University of Florence, Florence, Italy; Don Carlo Gnocchi Foundation (P.A.M., G.F.G.), Onlus IRCCS, Florence, Italy; and Department of Clinical Medicine, Prevention and Applied Biotechnologies (G.S., G.M., G.P.), University of Milano-Bicocca and Istituto Auxologico Italiano, Milan, Italy.

Correspondence to Professor Pietro Amedeo Modesti, MD, PhD, Clinica Medica Generale e Cardiologia, University of Florence, Viale Morgagni 85, 50134 Florence, Italy. E-mail pamodesti{at}unifi.it

Received December 1, 2005; revision received June 23, 2006; accepted July 1, 2006.

Background— The degree of pulmonary hypertension in healthy subjects exposed to acute hypobaric hypoxia at high altitude was found to be related to increased plasma endothelin (ET)-1. The aim of the present study was to investigate the effects of ET-1 antagonism on pulmonary hypertension, renal water, and sodium balance under acute and prolonged exposure to high-altitude–associated hypoxia.

Methods and Results— In a double-blind fashion, healthy volunteers were randomly assigned to receive bosentan (62.5 mg for 1 day and 125 mg for the following 2 days; n=10) or placebo (n=10) at sea level and after rapid ascent to high altitude (4559 m). At sea level, bosentan did not induce any significant changes in hemodynamic or renal parameters. At altitude, bosentan induced a significant reduction of systolic pulmonary artery pressure (21±7 versus 31±7 mm Hg, P<0.03) and a mild increase in arterial oxygen saturation versus placebo after just 1 day of treatment. However, both urinary volume and free water clearance (H₂OCl/glomerular filtration rate) were significantly reduced versus placebo after 2 days of ET-1 antagonism (1100±200 versus 1610±590 mL; –6.7±3.5 versus –1.8±4.8 mL/min, P<0.05 versus placebo for both). Sodium clearance and segmental tubular function were not significantly affected by bosentan administration.

Conclusions— The present results indicate that the early beneficial effect of ET-1 antagonism on pulmonary blood pressure is followed by an impairment in volume adaptation. These findings must be considered for the prevention and treatment of acute mountain sickness.

---

 

CLINICAL PERSPECTIVE

This article has been cited by other articles:

				P. Agostoni, G. Caldara, M. Bussotti, M. Revera, M. Valentini, F. Gregorini, A. Faini, C. Lombardi, G. Bilo, A. Giuliano, et al. Continuous positive airway pressure increases haemoglobin O2 saturation after acute but not prolonged altitude exposure Eur. Heart J., November 10, 2009; (2009) ehp472v1. [Abstract] [Full Text] [PDF]

				C. Hernandez, B. Rodriguez, E. Losada, L. Corraliza, M. Garcia-Ramirez, and R. Simo Normoalbuminuric Type 1 Diabetic Patients with Retinopathy Have an Impaired Tubular Response to Desmopressin: Its Relationship with Plasma Endothelin-1 J. Clin. Endocrinol. Metab., June 1, 2009; 94(6): 2060 - 2065. [Abstract] [Full Text] [PDF]

				V. Faoro, S. Boldingh, M. Moreels, S. Martinez, M. Lamotte, P. Unger, S. Brimioulle, S. Huez, and R. Naeije Bosentan Decreases Pulmonary Vascular Resistance and Improves Exercise Capacity in Acute Hypoxia Chest, May 1, 2009; 135(5): 1215 - 1222. [Abstract] [Full Text] [PDF]

				A. P. Comellas, A. Briva, L. A. Dada, M. L. Butti, H. E. Trejo, C. Yshii, Z. S. Azzam, J. Litvan, J. Chen, E. Lecuona, et al. Endothelin-1 Impairs Alveolar Epithelial Function via Endothelial ETB Receptor Am. J. Respir. Crit. Care Med., January 15, 2009; 179(2): 113 - 122. [Abstract] [Full Text] [PDF]

				N. P. Talbot, G. M. Balanos, P. A. Robbins, and K. L. Dorrington Can intravenous endothelin-1 be used to enhance hypoxic pulmonary vasoconstriction in healthy humans? Br. J. Anaesth., October 1, 2008; 101(4): 466 - 472. [Abstract] [Full Text] [PDF]

				A. K. Lund, L. N. Agbor, N. Zhang, A. Baker, H. Zhao, G. D. Fink, N. L. Kanagy, and M. K. Walker Loss of the Aryl Hydrocarbon Receptor Induces Hypoxemia, Endothelin-1, and Systemic Hypertension at Modest Altitude Hypertension, March 1, 2008; 51(3): 803 - 809. [Abstract] [Full Text] [PDF]

				B. Petersen, M. Deja, R. Bartholdy, B. Donaubauer, S. Laudi, R. C. E. Francis, W. Boemke, U. Kaisers, and T. Busch Inhalation of the ETA receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2008; 294(2): R601 - R605. [Abstract] [Full Text] [PDF]

				L. J. Rubin Endothelin-1 and the Pulmonary Vascular Response to Altitude: A New Therapeutic Target? Circulation, September 26, 2006; 114(13): 1350 - 1351. [Full Text] [PDF]